Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

Hepatitis B (Keep)

Preventing Hepatitis B Reactivation Due to Immunosuppressive Drug Treatments

Reactivation of hepatitis B virus infection can have devastating consequences, especially amongst those patients receiving immunosuppressive therapy.

Read Article

Knee Replacement and the Physical Terrorist

Experience is a great teacher.  My experience with knee replacement surgery has taught me the integral importance of the physical therapist in individual outcomes.

Read Article
coding3.jpg

New CPT Chronic Disease Management Code 99490

The new Medicare Physician Fee Schedule will allow for reimbursement for chronic care management services (CCM).

Read Article

Ten Pregnancy Takeaways from the ACR Reproductive Health Summit

In January 2014 the ACR convened a "Reproductive Health Summit" in Washington, DC to examine our understanding and knowledge of Pregnancy and Lactation issues in women with Rheumatic diseases.   Key Stakeholders from the FDA, NIH, Womens advocacy groups, Dermatology, Gastrenterology, ACR and Pharma were asked to discuss what is know and what our unmet needs are. 

Read Article
CHIKungunya_States.jpg

Chikungunya rises in the US and Worldwide

The chikungunya epidemic has grown significantly in the Western hemisphere with an additional 3,000 cases worldwide during the past week.

Read Article
psA.fil_.toes_.jpg

Psoriatic Arthritis Has a New FDA Approved DMARD - Apremilast

In March 2014 the FDA approved apremilast (Otezla) for use in psoriatic arthritis based on three large"Palace" trials involving 1493 psoriatic arthritis patients. This ACR Hotline reviews the drugs use, efficacy, and toxicity.

Read Article
MAS.jpg

Hemophagocytic Syndrome in Adults

Hemophagocytic lymphohistiocytosis(HLH) is a rare complication of many disorders. In children, systemic JIA is by far the most common cause of HLH.

Read Article
celebrex.jpg

Celebrex Goes Generic

The generic drug manufactuer Actavis joins Teva and Mylan with their lauch of celecoxib (Celebrex)in 50 mg, 100 mg, 200 mg and 400 mg capsules. In 2013 celecoxib was the 21st leading prescribed drug in the U.S. with $2.4 billion in sales as of mid 2014.

Read Article
×